Sniper Droplet-based Digital PCR
- Proprietary VibroJect™ Technology
Efficient, fast and reliable droplet generation of thousands of uniform volume partitions. Quality control for every well and every run
Seeing is believing
Maximimum sample utilization and minimal dead volume for the ultimate sensitivity
Peak performance
Fully Automated droplet generation, cycling and read off workflow
Development
Digital PCR (dPCR) is revolutionizing oncology and liquid biopsy testing by enabling precise, non-invasive cancer diagnostics. In oncology, it enables the detection in circulating tumor DNA (ctDNA) to identify rare mutations, monitor therapy resistance, and track tumor evolution, supporting personalized treatment strategies. dPCR also enhances the detection of minimal residual disease (MRD) and early relapse.
While tumor-based personalized healthcare testing has evolved to a standard of care in most developed country, multi-gene testing remains exorbitant in most part of Asia. This is further aggravated with complex laboratory processes
​
The development team seek the exploit the simple workflow of dPCR, multiplex capability, cost effectiveness and easy access to clinical blood specimen to enhance existing tumor-based testing options.
RUO dPCR Assay
Project based request to develop digital PCR (dPCR) assays that are wet lab validated based on intended specimen types such as cfDNA or FFPE tissues.
Oncology Assays
R3Charge dPCR Assay includes a library of common onoclogy targets that have been optimized to support cfDNA and challenging specimen. Reach out to us to find out more about the assays available
Oncology Panels
In the realm of oncology testing, the standard of care require a more comprehensive, multi-target solution which is catered to the specific testing need. In view of that, we have constructed specific panel tailoring to the clinical gap identified.